Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Profound Medical Corp PROF


Primary Symbol: T.PRN

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.


TSX:PRN - Post by User

Comment by HomerAndCompanyon Oct 08, 2021 7:13am
137 Views
Post# 33987539

RE:RE:RE:RE:RE:RE:RE:RE:Target 25 installations by YE, up from 14 as of Q2 Conf Call

RE:RE:RE:RE:RE:RE:RE:RE:Target 25 installations by YE, up from 14 as of Q2 Conf Call
MrMugsy wrote:
HomerAndCompany wrote:
MrMugsy wrote: Just listened to the Q2 again.

Today - 14 installs with 10 treating patients (USA).
20 new installs over the next 12 months.
Approximately 25 installs in the USA by end of 2021.

-----

Thanks again.


Thank you MrMugsy!

They said that they'd be doing 7-8 installations per quarter in 2022 (and then up to 10 per quarter after 2022) with the doubled (by Q3 2021) sales and installation teams. That rate of 7-8 installations per quarter must be what they ramp up to late in 2022, otherwise just 20 installs over the next 12 months seems low.
It also seems low given that they expect to go from 14 to 25 installations in the last 5 months of 2021.

Did you catch what they said about number of treatments per site and how that would evolve?

-TIA!



Yes !
Treatments per site ... 40 per year to start ... some are now at 60-70 (or more) per year ... goal is 100 per year per site.

Arun has 100 sites on his mind but I didn't catch how long it would take to get there.
He talks about ... 100 sites x 100 procedures/yr x $7,700 per ablation.

Also said they signed 6 new hospital deals for later this year (must be part of the 25 expected).

And ...Bringing Sonalleve to the USA next year.  Evaluating a numer of applications.  Selling units in Europe right now.

(I likely mixing information here from both the Q2 CC and the Cantor Health Conference)



Those numbers makes sense. If you take the 1.2 million Q2 revenue and divide it by 10 sites treating patients and then divide that by $7710 per treatment you get 16 treatments average per site in Q2.

That's an average of 64 treatments per site on an annualized basis. So it would seem that these 10 sites are already well on their way to that goal of 100 per year per site - which would be $771,000 or more in revenue per site.

-GLTA!
<< Previous
Bullboard Posts
Next >>